International Stem Cell AI Stock Analysis
Want to see ISCO full AI Analyst Report?
International Stem Cell (ISCO) AI Stock Analysis
International Stem Cell
(Other OTC:ISCO)
Score dragged down by poor financial performance including chronic losses and cash burn risks; partially offset by attractive low P/E valuation and stable technicals above moving averages.
International Stem Cell (ISCO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 36.86K
- Price to Earnings (P/E)
- -2.5
- Beta (1Y)
- -1.09
- Revenue Growth
- 3.40%
- EPS Growth
- -101.06%
- Country
- US
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
International Stem Cell Business Overview & Revenue Model
Company Description
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products...
How the Company Makes Money
ISCO has historically generated revenue through multiple sources tied to its stem cell platforms: (1) sales of stem cell–related products and services (e.g., cell lines, cell-based materials, and/or contract services supporting research and developme...
International Stem Cell Financial Statement Overview
Summary
Low score reflects weak Income Statement (35), Balance Sheet (28), and Cash Flow (42) scores, driven by persistent net losses, equity volatility, high leverage risks, and inconsistent cash flows despite modest revenue growth.
Income Statement
35NegativeBalance Sheet
28NegativeCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.51M | 9.10M | 9.09M | 7.79M | 8.18M | 7.18M |
| Gross Profit | 5.22M | 5.07M | 5.32M | 4.61M | 4.91M | 4.24M |
| EBITDA | -162.00K | -48.00K | 142.00K | 202.00K | 22.00K | -509.00K |
| Net Income | -582.00K | -418.00K | -209.00K | -131.00K | -466.00K | -1.04M |
Balance Sheet | ||||||
| Total Assets | 5.06M | 4.82M | 5.17M | 5.39M | 5.13M | 4.95M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 993.00K | 1.23M | 1.59M | 742.00K | 171.00K |
| Total Debt | 3.46M | 3.73M | 3.84M | 4.18M | 4.28M | 4.07M |
| Total Liabilities | 4.98M | 8.88M | 9.10M | 5.28M | 9.65M | 9.53M |
| Stockholders Equity | 72.00K | -4.06M | -3.93M | 113.00K | -4.52M | -4.59M |
Cash Flow | ||||||
| Free Cash Flow | 333.00K | -35.00K | -153.00K | 846.00K | 321.00K | -1.34M |
| Operating Cash Flow | 369.00K | 8,000 | 13.00K | 929.00K | 332.00K | -1.30M |
| Investing Cash Flow | -50.00K | -45.00K | -171.00K | -83.00K | -11.00K | -45.00K |
| Financing Cash Flow | -150.00K | -200.00K | -200.00K | 0 | 250.00K | 824.00K |
International Stem Cell Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISCO, the sentiment is Neutral. The current price of 0.16 is above the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.25, and below the 200-day MA of 0.22, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.78 is Neutral, neither overbought nor oversold. The STOCH value of 57.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ISCO.
International Stem Cell Risk Analysis
International Stem Cell disclosed 55 risk factors in its most recent earnings report. International Stem Cell reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksInternational Stem Cell Peers Comparison
Overall Rating
ISCO57Neutral
CELU47Neutral
MBIO43Neutral
LGVN39Underperform
MRKR39Underperform
BRTX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | $1.28M | -2.54 | 19.43% | ― | 3.40% | -101.06% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $18.53M | -0.27 | 142.25% | ― | -58.14% | 47.25% | |
| 43Neutral | $2.88M | -0.74 | -43.76% | ― | ― | 59.14% | |
| 39Underperform | $6.71M | -0.24 | -243.26% | ― | -18.93% | 39.19% | |
| 39Underperform | $14.23M | -1.85 | -64.24% | ― | -76.50% | 62.83% | |
| 38Underperform | $1.83M | -0.06 | -423.84% | ― | -8.47% | 25.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ISCO | International Stem Cell Corp | 0.16 | 0.01 | 6.00% | |
| MRKR | Marker Therapeutics | 0.85 | -0.14 | -14.19% | |
| MBIO | Mustang Bio | 0.38 | -0.77 | -66.96% | |
| BRTX | Biorestorative Therapies, Inc. | 1.32 | -20.88 | -94.03% | |
| CELU | Celularity Inc. | 0.48 | -1.23 | -71.75% | |
| LGVN | Longeveron Inc. | 1.92 | -4.11 | -68.18% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Mar 31, 2026
